Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.68 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL2323247 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL723255 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL8845240 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL5320793 | 0.92 | SLC7A5 (0.58) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL4409201 | 0.92 | SLC7A5 (0.58) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL5320799 | 0.92 | SLC7A5 (0.58) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL4409187 | 0.92 | SLC7A5 (0.58) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Valine SCHEMBL27494283 | 0.90 | PTGS1 (0.59) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Leucine SCHEMBL26626981 | 0.90 | SLC7A5 (0.67) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 | |
| Isoleucine SCHEMBL7722171 | 0.89 | SLC7A5 (0.54) | SLC7A5SLC1A1SLC1A3SLC1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332119-A2 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | Novo Nordisk A/S (DK) | 2024-03-06 | — | — | EP | claimed |
| US-20170298130-A1 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | NOVO NORDISK A/S (DK) | 2017-10-19 | — | — | US | claimed |
| EP-3172232-A1 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | Novo Nordisk A/S (DK) | 2017-05-31 | — | — | EP | claimed |
| EP-3026061-A1 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY. | NOVO NORDISK A/S (DK) | 2016-06-01 | — | — | EP | claimed |
| WO-2016009086-A1 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | NOVO NORDISK A/S (DK) | 2016-01-21 | — | — | WO | claimed |
| EP-2975056-A1 | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity | NOVO NORDISK A/S (DK) | 2016-01-20 | — | — | EP | claimed |
| US-20050214907-A1 | Immunoglobulins and method for their modification | UNILEVER BESTFOODS NORTH AMERICA, DIVISION OF CONOPCO, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005075515-A2 | IMMUNOGLOBULINS AND METHOD FOR THEIR MODIFICATION | UNILEVER N.V. (NL) | 2005-08-18 | — | — | WO | claimed |
| EP-4332119-A2 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | Novo Nordisk A/S (DK) | 2024-03-06 | — | — | EP | disclosed |
| US-20220010012-A1 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | NOVO NORDISK A/S (DK) | 2022-01-13 | — | — | US | disclosed |
| US-20210253644-A1 | CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-08-19 | — | — | US | disclosed |
| US-11072654-B2 | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity | NOVO NORDISK A/S (DK) | 2021-07-27 | — | — | US | disclosed |
| US-10934327-B2 | Capsid-modified, RAAV3 vector compositions and uses in gene therapy of human liver cancer | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-03-02 | — | — | US | disclosed |
| CN-111763690-A | Capsid-modified RAAV3 vector compositions and uses in gene therapy of human liver cancer | 佛罗里达大学研究基金会有限公司 | 2020-10-13 | — | — | CN | disclosed |
| US-RE37381-E1 | ATTENUATED CDNA SEQUENCE; GENETIC ENGINEERING; MUTANTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-09-18 | — | — | US | disclosed |
| WO-2000049889-A1 | ANIMAL FEED SUPPLEMENT FOR THE NUTRITIONAL ENRICHMENT OF ANIMAL PRODUCE | BARTLETT GRAIN PTY. LTD. (AU) | 2000-08-31 | — | — | WO | disclosed |
| US-5747652-A | Antibody to smooth muscle myosin heavy chains | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| WO-1996035444-A1 | NOVEL PEPTIDES FOR HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN ANTICOAGULATION REVERSAL | UNIVERSITY OF MICHIGAN (US) | 1996-11-14 | — | — | WO | disclosed |
| US-5109123-A | Alteration of ability of soluble CD4 fragments to bind HIV | DANA FARBER CANCER INSTITUTE (US) | 1992-04-28 | — | — | US | disclosed |
| US-3940479-A | BACILLUS POLYMYXA | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934327-B2 | Capsid-modified, RAAV3 vector compositions and uses in gene therapy of human liver cancer | HAVCR2, HDGF, HCCS | SLC7A5 4495/4885SLC1A1 3812/4885SLC1A3 3863/4885 |
| US-20210253644-A1 | CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER | HAVCR2, HDGF, HCCS | SLC7A5 4520/4885SLC1A1 4053/4885SLC1A3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.